2019-nCoV Clinical Trial
Official title:
Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. The number of cases of infection with 2019-nCoV identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Mathematical models of the expansion phase of the epidemic suggested that sustained person-to-person transmission is occurring, and the R-zero is substantially above 1, the level required for a self-sustaining epidemic in human populations. There is currently no specific treatment for 2019-ncov-infected pneumonia. Arbidol tablet is a non-nucleoside broad-spectrum antiviral drug with immune-enhancing effect. Abidor is pharmacodynamic in vitro against a variety of coronaviruses.This is a randomized, open, multicenter clinical study of pneumonic subjects diagnosed with 2019-ncov infection. The main objective was to compare the viral negative conversion rate in the first week after the subjects were randomized to arbidol plus basic treatment. In this study, 380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio. patients will receive one of two treatment regimens: A .Abidor tablets + basic treatment B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT04334967 -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
|
Phase 4 | |
| Not yet recruiting |
NCT04264858 -
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
|
N/A | |
| Withdrawn |
NCT04272710 -
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
|
||
| Active, not recruiting |
NCT04273763 -
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
|
N/A | |
| Not yet recruiting |
NCT04270383 -
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
|
||
| Terminated |
NCT04261907 -
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
|
N/A | |
| Not yet recruiting |
NCT04261426 -
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04254874 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
|
Phase 4 | |
| Recruiting |
NCT04255017 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT04356508 -
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
|
Phase 2 | |
| Terminated |
NCT04321928 -
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
|
N/A |